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Breast cancer is the most common cancer in females. Known breast cancer 
predisposition genes are BRCA1 and BRCA2. These genes are involved in the DNA 
damage response pathway, more specifically in homologous recombination (HR). HR 
is a DNA double strand break repair pathway active in S- and G2-phase of the cell 
cycle. Accumulation of RAD51 at the double strand break site is a hallmark of HR and 
could therefore be used to assess HR functionality and radiosensitivity in mutation 
carriers. 
A recent study performed by our group showed that in vitro irradiation of MCF10A 
breast epithelial cells with reduced BRCA1 and BRCA2 protein levels resulted in a 
significant decrease in RAD51 foci. 
 
Aim: 
Investigate if RAD51 foci can be used as biomarkers to assess HR functionality in 




PBMCs were isolated by density gradient centrifugation and cultured for 72h. The cells 
were irradiated with 5 Gy (220 kV X-rays). Identification of cells in S-phase at time of 
irradiation was achieved by EdU pulse-labelling. Thereafter RAD51 foci were detected 
by immunofluorescent staining and automatically scored by Metacyte software 
(Metafer 4, Metasystems). 
 
Conclusion 
The functional RAD51 foci assay was optimized. Preliminary results comparing RAD51 
foci between healthy individuals and mutation carriers will be presented. As 
BRCA1/BRCA2 mutation carriers might show increased risk for radiation-induced 
carcinogenesis, these results can ultimately contribute to personalized radiation 
regimens, both therapeutic as diagnostic. 
 
 
